Fugère Martin, Limperis Polizois C, Beaulieu-Audy Véronique, Gagnon Frédéric, Lavigne Pierre, Klarskov Klaus, Leduc Richard, Day Robert
Department of Pharmacology, Institut de Pharmacologie de Sherbrooke, Faculté de médecine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada.
J Biol Chem. 2002 Mar 8;277(10):7648-56. doi: 10.1074/jbc.M107467200. Epub 2001 Nov 26.
The SPCs (subtilisin-like pro-protein convertases) are a family of enzymes responsible for the proteolytic processing of numerous precursor proteins of the constitutive and regulated secretory pathways. SPCs are themselves synthesized as inactive zymogens. Activation of SPCs occurs via the intramolecular autocatalytic removal of the prodomain. SPC prodomains have been proposed as templates in the development of potent and specific SPC inhibitors. In this study, we investigated the specificity and potency of complete prodomains and short C-terminal prodomain peptides of each SPC on highly purified, soluble enzyme preparations of human SPC1, SPC6, and SPC7. Progress curve kinetic analysis of prodomain peptides and complete prodomains showed competitive inhibitory profiles in the low nanomolar range. Complete prodomains were 5-100 times more potent than C-terminal prodomain peptides, suggesting that N-terminal determinants are involved in the recognition process. However, complete prodomains and prodomain peptides exhibit only a partial specificity toward their cognate enzyme. Ala-scan structure activity studies indicated the importance of basic residues in the P(4), P(5), and P(6) positions for inhibition of SPC1. In contrast, hydrophobic residues in P(6) and P(7), as well as basic residues in P(4) and P(5), were critical for inhibition of SPC7. Our data demonstrated that the use of prodomains as specific inhibitors acting in trans would be of limited usefulness, unless modified into more specific compounds.
枯草杆菌蛋白酶样前体蛋白转化酶(SPCs)是一类负责组成型和调节型分泌途径中众多前体蛋白进行蛋白水解加工的酶家族。SPCs自身以无活性的酶原形式合成。SPCs的激活通过分子内自催化去除前结构域来实现。SPC前结构域已被提议作为开发强效且特异性SPC抑制剂的模板。在本研究中,我们研究了每种SPC的完整前结构域和短C末端前结构域肽对人SPC1、SPC6和SPC7的高度纯化的可溶性酶制剂的特异性和效力。前结构域肽和完整前结构域的进展曲线动力学分析显示在低纳摩尔范围内具有竞争性抑制特征。完整前结构域的效力比C末端前结构域肽高5至100倍,这表明N末端决定簇参与了识别过程。然而,完整前结构域和前结构域肽对其同源酶仅表现出部分特异性。丙氨酸扫描结构活性研究表明,P(4)、P(5)和P(6)位置的碱性残基对于抑制SPC1很重要。相比之下,P(6)和P(7)位置的疏水残基以及P(4)和P(5)位置的碱性残基对于抑制SPC7至关重要。我们的数据表明,除非将前结构域修饰成更具特异性的化合物,否则将其用作反式作用的特异性抑制剂的用途将有限。